Astellas Pharma Inc.
Research Astellas Pharma Inc. (4503.T) on Bullrun: market cap JPY 4.34T, P/E 11.9, dividend yield 3.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4503.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 4.34T
- P/E11.9
- Dividend yield3.3%
- Financial periodFY2026
- RevenueJPY 2.14T
- Revenue growth11.9%
- Net incomeJPY 291.54B
- Free cash flowJPY 475.54B
- Gross margin80.9%
Valuation Snapshot
latest market cap is JPY 4.34T; P/E is 11.9; dividend yield is 3.3%.
Peer valuation comparison
Latest P/E is 11.91x versus a Healthcare sector median of 21.69x (45.1% below).
Latest dividend yield is 3.25% versus a Healthcare sector median of 2.41% (34.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 2.14T | JPY 291.54B | JPY 475.54B | 80.9% | 162.22 | JPY 281.61B | JPY 565.95B | JPY 1.83T |
| FY2025 | JPY 1.91T | JPY 50.75B | JPY 137.18B | 81.7% | 28.24 | JPY 188.37B | JPY 831.43B | JPY 1.51T |
| FY2024 | JPY 1.60T | JPY 17.05B | JPY 89.98B | 81.8% | 9.47 | JPY 335.69B | JPY 920.02B | JPY 1.60T |
| FY2023 | JPY 1.52T | JPY 98.71B | JPY 239.23B | 81.0% | 54.09 | JPY 376.84B | JPY 125.00B | JPY 1.51T |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 4.34T | 11.9 | 3.3% | 80 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 80 JPY, yield 3.3%.
| Year | Dividends/share |
|---|---|
| FY2026 | 79 JPY |
| FY2025 | 76 JPY |
| FY2024 | 72 JPY |
| FY2023 | 65 JPY |
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause;
ETFs that hold Astellas Pharma Inc.
Astellas Pharma Inc. is one of the ten largest holdings of 5 ETFs that investors in Europe can buy, most traded first:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Astellas Pharma Inc.'s market cap?
Astellas Pharma Inc.'s market capitalization is JPY 4.34T.
What is Astellas Pharma Inc.'s P/E ratio?
Astellas Pharma Inc.'s price-to-earnings (P/E) ratio is 11.9.
Does Astellas Pharma Inc. pay a dividend?
Astellas Pharma Inc. has a dividend yield of 3.3%.
What does Astellas Pharma Inc. do?
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma.